Britain became the first country to vaccinate its population with Oxford University and AstraZeneca’s Covid-19 shot on Jan. 4, but Prime Minister Boris Johnson was set to tighten restrictions in England in a bid to slow the spread of cases.
Economic relief and a vaccine drew nearer to reality to counter a coronavirus pandemic that has ravaged the U.S. economy and killed 286,487 people with year-end holiday gatherings expected to fuel another surge in infections.
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion.
Late-stage trial results of a potential Covid-19 vaccine being developed by the University of Oxford and AstraZeneca could be presented in 2020 as the British government prepares for a possible vaccination rollout in late December or early 2021.
Businesses, professional bodies and individual practitioners have to keep talking at a time like this, not least because patients’ non-Covid-related needs have not disappeared overnight. How are lines of communication holding up, and what might this tell us about life after Covid-19?
The first ever clinical study evaluating combined transcranial direct current stimulation (tDCS) and behaviour therapy could point to a new treatment for depression.
Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.
England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.
The U.S. FDA approved AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older during 2017.
With a goal of eradicating hepatitis C, NHS England has teamed up Gilead Sciences Inc., Merck & Co. and AbbVie Inc.